Skip to main content
. 2012 Feb 15;287(15):12331–12342. doi: 10.1074/jbc.M112.346791

FIGURE 1.

FIGURE 1.

Erg represses ICAM-1 and binds to the ICAM-1 promoter region 4 in resting EC. A and B, HUVEC were treated with siRNA for Erg, Fli-1, Ets-2, or GABPα for 24 h; relative expression of Erg, Fli-1, Ets-2, and GABPα mRNA (A) or ICAM-1 mRNA (B) was quantified by RT-PCR and expressed as relative to control siRNA treatment (Cont). C, analysis of 1.3 kb of the ICAM-1 promoter identified putative EBS, Erg consensus sites, AP1/ETS sites, and an NF-κB site as indicated. Location of quantitative PCR amplicons covering R1, R2, R3, R4, and R5 are indicated by black lines below. D and E, ChIP was carried out using an anti-Erg or control IgG antibody on sheared chromatin from confluent resting HUVEC (D) or HUVEC treated with Erg or control siRNA (E). Immunoprecipitated DNA was analyzed by qPCR for primers covering ICAM-1 promoter regions 1–5 (D) or region 4 only (E) and negative control region. Results are expressed as fold-change compared with IgG normalized to input and negative control region. n = 6 (B), n = 5 (C), *, p < 0.05; **, p < 0.01; ***, p < 0.001.